European Consortium develops innovative test to predict the COVID-19 impact in the heart

A team led by CNC group leader Lino Ferreira integrates an European research consortium which seeks to develop a new diagnostic test to identify COVID-19 patients that may be prone to develop fatal cardiovascular complications.

Named “COVIRNA – A diagnostic test to ameliorate the surveillance and treatment of COVID-19 patients”, the project has a duration of 2 years, and has a 3.9 million euros worth of financing from the European Union, within the action plan ERAvsCorona, which promotes the cooperation between European research institutions to strengthen the pandemic response.

Know more here:
Funded by ERDF - European Regional Development Fund through COMPETE 2020 and National Funds via FCT - Fundação para a Ciência e Tecnologia, under projects POCI-01-0145-FEDER-007440 e UIDB/04539/2020.

© 2021 CNC - Center for Neuroscience and Cell Biology
powered by DigitalWind